GSK ranks 2nd in 2026 Access to Medicine Index reinforcing commitment to responsible access to its medicines and vaccines

10 November 2026

• 2026 marks two decades of consistent top-tier GSK ranking in the ATMI

• GSK recognised as having the largest priority disease R&D pipeline across industry

GSK is pleased to again rank among the leading companies in the Access to Medicine Index (ATMI) in its 20th year. The Index is an independent, investor-backed report that ranks 20 of the world’s largest pharmaceutical companies on progress to improve access in 113 low- and middle- income countries.

GSK ranked 2nd overall and in the top two companies in all categories measured, remaining the company with the largest priority disease R&D pipeline in the industry.

Lynn Baxter, CEO of ViiV and President of GSK Global Health, said: “The ATMI is an important and widely recognised benchmark of how we are advancing innovation and strengthening access to medicines and vaccines. We are very proud that throughout the 20 years of ATMI reporting, GSK has been consistently recognised as high-performing across all categories measured. Partnership and collaboration are at the heart of our approach to access in low and middle-income countries, working with a range of organisations to help our innovations reach the people who need them. We are grateful to those partners and delighted that this shared commitment is reflected in the ATMI report.”

GSK 2026 ATMI highlights:

• Our comprehensive approach to access to medicines places us in the top two companies across all three technical areas measured in by ATMI.

• We continue to be recognised as a global leader in infectious diseases, with the largest priority disease R&D pipeline across industry, leveraging our science and innovation to change the trajectory of tuberculosis, malaria and HIV, and to get ahead of AMR.

• Our strong performance in Product Delivery, which assesses how companies improve access to their products, recognises the variety of mechanisms we use to broaden access, including IP sharing, voluntary licensing, registration and capacity building across manufacturing, supply chain and health system strengthening. This reflects our work with key partners like Gavi, UNICEF, the Medicines Patent Pool, Amref, Last Mile Health, Save the Children and others, to ensure our products can be accessed across different country income classifications, addressing the highest areas of burden and unmet need.

Further recent momentum in GSK/ViiV access initiatives

• A new equitable access agreement between Gavi, UNICEF and Bharat Biotech (BBIL), announced in October 2026 for the GSK-developed malaria vaccine, RTS,S/AS01, will cut the price of the vaccine by 40%, generating around $50m in savings to child immunisation programmes (2027-29), and enable vaccination of an estimated 1m more children. The agreement follows $200m in investment by GSK and BBIL in new, higher-output manufacturing facilities, product development and technology transfer to expand and strengthen supply at a lower cost.

• Also in October, ViiV Healthcare announced an agreement with Axmed, a technology-enabled B2B marketplace and logistics platform that connects buyers, manufacturers, and distributors to streamline procurement and delivery of HIV medicines across low- and middle-income countries. Through the agreement, Axmed will allow local governments and healthcare institutions in over 50 middle-income countries to purchase ViiV Healthcare medicines. With most new HIV cases reported in low- and middle-income countries, this agreement is an example of how we are expanding choice and access to HIV care options.